文献速递免疫规划传染病防控与疫情报告

表达PCV2 Cap蛋白的重组减毒PRRSV疫苗在猪中诱导保护性免疫

A recombinant attenuated PRRSV vaccine expressing the PCV2 capsid protein confers protective immunity in pigs.
PubMed 文献 · Vaccine · 2026-08-31

本研究以减毒PRRSV株HuN4-F112为载体表达PCV2d Cap蛋白,构建重组病毒rHuN4-F112-Cap。在仔猪中单次肌注可诱导PRRSV和PCV2特异性抗体及PCV2中和抗体;分别攻毒后,接种组较DMEM对照组PCV2 DNA载量降低、淋巴病变减轻,高致病性PRRSV攻毒后临床症状减轻、RNA载量降低、肺部病变减轻且存活率提高。

要点

  • 重组减毒PRRSV载体可同时诱导PRRSV与PCV2特异性免疫应答。
  • 单次肌注即可在攻毒前产生PCV2中和抗体。
  • 攻毒保护:PCV2载量与病变降低,HP-PRRSV存活率提高。

核心结论

  • rHuN4-F112-Cap可作为针对PRRSV和PCV2的二价活载体疫苗候选。

研究设计与样本

  • 以减毒PRRSV株HuN4-F112为活病毒载体,通过反向遗传系统拯救表达PCV2d Cap蛋白的重组病毒rHuN4-F112-Cap。
  • 在MARC-145细胞中比较重组病毒与亲本株生长特性,并确认PCV2 Cap基因表达。
  • 仔猪单次肌注重组病毒,评估PRRSV和PCV2特异性抗体及PCV2中和抗体。
  • 分别进行PCV2攻毒和高致病性PRRSV攻毒模型,与DMEM接种对照比较。

主要发现

  • rHuN4-F112-Cap在MARC-145细胞中生长特性与亲本HuN4-F112株相当,且插入的PCV2 Cap基因表达得到确认。
  • 仔猪单次肌注rHuN4-F112-Cap诱导PRRSV和PCV2特异性抗体反应,以及攻毒前PCV2中和抗体。
  • PCV2攻毒后,接种仔猪较DMEM对照组PCV2 DNA载量降低、淋巴病变减轻。
  • 高致病性PRRSV攻毒后,接种仔猪较DMEM对照组临床症状减轻、PRRSV RNA载量降低、肺部病变减轻且存活率提高。

临床怎么用

  • 提示单次免疫即可同时针对PRRSV和PCV2诱导免疫应答,可能简化免疫程序并减少动物抓取。
  • 目前证据来自猪模型实验,尚需进一步临床/田间评估后方可用于养猪场免疫决策。

局限性

  • 原文未报告样本量、具体抗体滴度、病毒载量数值、病变评分及P值等定量数据。
  • 研究为实验性攻毒模型,未提供田间大规模应用数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus type 2 (PCV2) are major swine pathogens that cause severe disease and frequently occur as coinfections in pig herds. Current vaccination strategies against PRRSV and PCV2 commonly rely on separate vaccines, which may increase the complexity of immunization programs and require repeated animal handling. Therefore, a bivalent vaccine platform capable of inducing immune responses against both pathogens would be valuable for simplifying vaccination strategies. In this study, the attenuated PRRSV strain HuN4-F112 was used as a live viral vector to express the PCV2d capsid (Cap) protein. The recombinant virus rHuN4-F112-Cap was successfully rescued using a reverse-genetics system. rHuN4-F112-Cap showed growth characteristics comparable to those of the parental HuN4-F112 strain in MARC-145 cells, and expression of the inserted PCV2 Cap gene was confirmed. A single intramuscular immunization with rHuN4-F112-Cap induced PRRSV and PCV2 specific antibody responses in piglets, as well as PCV2-neutralizing antibodies before challenge. In separate challenge models, vaccinated piglets showed reduced PCV2 DNA loads and milder lymphoid lesions after PCV2 challenge, and reduced clinical signs, lower PRRSV RNA loads, milder pulmonary lesions, and improved survival after highly pathogenic PRRSV challenge compared with DMEM-inoculated controls. These findings indicate that rHuN4-F112-Cap has potential as a bivalent live-vector vaccine candidate against PRRSV and PCV2.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gao SL, Yan JC, Wang J, et al. A recombinant attenuated PRRSV vaccine expressing the PCV2 capsid protein confers protective immunity in pigs. Vaccine. 2026. PMID: 42673712. doi:10.1016/j.vaccine.2026.129106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。